Abstract Number: 0842 • ACR Convergence 2024
The Incident Risk and Predictors of Systemic Autoimmune Rheumatic Disease (SARD) Development in Persistently Antiphospholipid Antibody Positive Patients Without SARDs: Prospective Results from the APS ACTION Clinical Database and Repository (“Registry”)
Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases…Abstract Number: 0106 • ACR Convergence 2024
IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…Abstract Number: 0122 • ACR Convergence 2024
Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome
Background/Purpose: Growth differentiation factor 15 (GDF-15), is a stress induced inflammatory cytokine, member of the transforming growth factor-β superfamily, tissue injury. It is predominantly expressed…Abstract Number: 0915 • ACR Convergence 2024
APOH Locus Associated with Higher Anti-Beta-2-Glycoprotein 1 Antibody Levels Paradoxically Protects Against Venous Thromboembolism
Background/Purpose: Anti-Beta-2-glycoprotein 1 antibody (anti-B2GP1) is associated with antiphospholipid syndrome (APS), a rare autoimmune disease that causes venous thromboembolism (VTE). APOH, which expresses the B2GP1…Abstract Number: 0107 • ACR Convergence 2024
Screening for Non-criteria Antiphospholipid Autoantibodies in Patients Younger Than 50 Years Old Admitted for Venous Thromboembolism: A Cross-sectional Study
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of thromboses and/or pregnancy morbidity in the presence of persistent antiphospholipid autoantibodies (aPL)…Abstract Number: 0123 • ACR Convergence 2024
The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS)
Background/Purpose: PAPS is an autoimmune disease marked by thrombosis, obstetric poor outcomes and antiphospholipid antibodies. Despite treatment, APS is associated with high morbidity and mortality,…Abstract Number: 1111 • ACR Convergence 2024
Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism
Background/Purpose: Autoimmune diseases are associated with a high prevalence of pulmonary embolism due to the inflammation-induced hyper coagulable state.This study aimed to analyze trends in…Abstract Number: 0108 • ACR Convergence 2024
Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…Abstract Number: 0124 • ACR Convergence 2024
Sexual Health Challenges in Primary Antiphospholipid Syndrome: Exploring Prevalence and Clinical Correlates
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic thromboinflammatory disease with various forms of presentation. There is limited information on sexual function in patients with APS,…Abstract Number: 1240 • ACR Convergence 2024
Living with Antiphospholipid Antibodies: A Photovoice Exploration
Background/Purpose: The diverse manifestations of antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPLs) exert substantial but poorly understood impacts on the lives of those affected. This…Abstract Number: 0109 • ACR Convergence 2024
Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are characterized by heterogenous clinical presentations, driven by autoantibodies; patients with SLE develop APS more often…Abstract Number: 0125 • ACR Convergence 2024
Electronic Health Record Rule-Based Computable Phenotype of Antiphospholipid Syndrome
Background/Purpose: Electronic health record (EHR) data provide a widely available, inexpensive, and information-rich tool that is underutilized in the research of rare diseases like antiphospholipid…Abstract Number: 1267 • ACR Convergence 2024
Antiphospholipid Antibody-related Clinical Manifestations Presenting During Childhood versus Adulthood: Descriptive Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: APS ACTION Registry studies long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic autoimmune rheumatic diseases. Given autoimmune diseases present differently in…Abstract Number: 0110 • ACR Convergence 2024
Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists
Background/Purpose: We have recently shown that anti-phospholipid (APL) assays of varying methodology demonstrate comparable analytical performance despite variable levels of agreement among individual analytes, identifying binding…Abstract Number: 0126 • ACR Convergence 2024
Underdiagnosis Prediction Fingerprint for Antiphospholipid Syndrome Derived from Electronic Health Record Data
Background/Purpose: Antiphospholipid syndrome (APS) is a rare autoimmune disease that is likely to demonstrate improved outcomes with earlier diagnosis and treatment. However, given APS’s complex,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 19
- Next Page »